Can-Fite BioPharma
  • ABOUT
    • Overview
    • Management
    • Drug Development Team
    • Board of Directors
    • Corporate Partnerships
  • SCIENCE
    • Technology Platform
    • Scientific Publications
  • PIPELINE
    • Overview
    • Piclidenoson (CF101)
    • Namodenoson (CF102)
    • CF602
    • Cannabinoids
  • INVESTORS
    • Overview
    • News & Events
    • Company Information
    • Financial Information
    • Stock Information
    • SEC Fillings
    • Corporate Governance
    • Shareholders Meetings
  • CONTACT

Press Releases

Investors

Investors

  • Overview
  • News & Events
    • Overview
    • Press Releases
    • In The News
    • Research
    • Events Calendar
    • Presentations
    • Email Alerts
  • Company Info
    • Overview
    • Management
    • Contacts
    • FAQ
  • Financial Info
    • Overview
    • Financial Results
  • Stock Data
    • Quote
    • Charts
    • Historical Data
  • SEC Filings
    • Overview
    • All SEC Filings
    • Section 16 Filings
  • Governance
    • Overview
    • Board of Directors
    • Governance Documents
  • Shareholders Meetings
  • News & Events

  • Overview
  • Press Releases
  • In The News
  • Research
  • Events Calendar
  • Presentations
  • Email Alerts
Nov 16, 2020 7:00am EST

Can-Fite Presented NASH Phase II Namodenoson Data at a Late Breaking Session of the American Association for the Study of Liver Diseases (AASLD) Conference

Nov 09, 2020 7:00am EST

Can-Fite to Present its NASH Program in Fireside Chat at the H.C. Wainwright 6th Annual Israel Conference on November 12, 2020

Oct 13, 2020 7:00am EDT

Can-Fite to Host Conference Call to Update Shareholders on Positive Interim Results of its Phase III Psoriasis Study on October 15, 2020

Oct 06, 2020 7:30am EDT

Can-Fite Announces Positive Phase III Psoriasis Interim Data Analysis

Sep 30, 2020 7:00am EDT

Can-Fite Selected to Deliver Late-Breaking Oral Presentation on Namodenoson’s Treatment of NASH at American Association for the Study of Liver Diseases Conference

Sep 22, 2020 7:00am EDT

Can-Fite to Participate in Two BioPharma Partnering Conferences

Sep 08, 2020 7:00am EDT

Can-Fite to Present at H.C. Wainwright 22nd Annual Global Investment Conference on September 14, 2020

Aug 31, 2020 7:00am EDT

FDA Clears Can-Fite to Commence Phase II COVID-19 Study

Aug 27, 2020 7:00am EDT

Can-Fite Reports Second Quarter 2020 Financial Results & Provides Clinical Update

Aug 26, 2020 7:00am EDT

Can-Fite to Present at The LD Micro 500 Virtual Conference on September 1, 2020

  • arrow_back
  • 1
  • …
  • 4
  • 5
  • 6
  • 7
  • 8
  • 9
  • 10
  • 11
  • 12
  • 13
  • …
  • 37
  • arrow_forward
rss_feed News RSS
  • Email Alerts
  • Contacts
  • RSS News Feed
  • HOME
  • CONTACT

© 2023 Can-Fite All Rights Reserved

BrandWiz - Branding